Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Abroad (travel likely)RecruitingPHASE3

Conditions

Hepatocellular Carcinoma (HCC) · Radiotherapy, Adjuvant · Immune Checkpoint Inhibitor · TACE · Narrow Margin

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Contact: Study coordinator (Bo Chen, MD) · chenboo@outlook.com · 00861324000876

Study leads

Shuhang Wang
Study Director
NCC, CICAMS

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma · Immune Checkpoint Inhibitors · Anti-angiogenic Therapy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Paris, France

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE3

Nanchang, China · Chifeng, China

HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE3

Foshan, China · Guangzhou, China